Vertex buys the top spot on the list of the biggest preclinical M&A deals. Were they robbed or was it a steal?
The odds of success for the average preclinical drug program are grim, as everyone in R&D can tell you. But that hasn’t stopped the deals in this space from gobbling up more and more cash.
Vertex’s $950 million cash deal to buy Semma and its preclinical stem cell program for diabetes — shooting for a potential cure that combines insulin-producing cells inside a “tea bag” tech for preventing them from sparking an immune response — shot straight to the top of the list of the biggest acquisitions of preclinical assets over the past decade.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
